Citadel Advisors
ERNA icon

Citadel Advisors’s Eterna Therapeutics ERNA Stock Holding History

Citadel Advisors’s Portfolio ERNA Stock Details ERNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-3
Closed -$216K – 14028
2021
Q3 		$216K Sell
3
-12
-80% -$1.04M ﹤0.01% 11825
2021
Q2 		$2.07M Buy
+15
New +$2.16M ﹤0.01% 6536

Other funds holding ERNA

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return
Corient Private Wealth
Corient Private Wealth Miami, Florida $69.9B AUM 22.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citadel Advisors's ERNA Position: Q1 2026 in Review

Citadel Advisors opened a new position in Eterna Therapeutics (ERNA) in Q1 2026: 1,323 shares worth $6.58K. The stake represents ﹤0.01% of the portfolio and ranks #12796 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in ERNA as recently as Q1 2025.

Citadel Advisors first reported a position in ERNA in Q3 2018 and has held it in 13 quarters since. The position peaked at $490K in Q4 2021. 15 funds tracked by Wall St. Rank hold ERNA as of Q1 2026.

  • Citadel Advisors held 1,323 shares of Eterna Therapeutics worth $6.58K as of Q1 2026.
  • Eterna Therapeutics was a new Citadel Advisors position in Q1 2026.
  • Eterna Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #12796 holding.
  • Citadel Advisors first reported a position in Eterna Therapeutics in Q3 2018 and has held it in 13 quarters since.
  • Citadel Advisors's Eterna Therapeutics position peaked at $490K in Q4 2021.
  • 15 funds tracked by Wall St. Rank held Eterna Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.